VolitionRx recently released data for NuQ in colorectal and lung cancer, which both exceeded results from previous trials. In colorectal cancer (CRC), the test when adjusted for age detected 91% of tumors with 90% specificity in its first completed prospective study, unlike previous retrospective studies. The company also released encouraging interim lung cancer data detecting 93% of tumors with 91% specificity using the NuQ test in combination with smoking history, which positions the test a
07 Jan 2016
New results boost NuQ for lung and CRC
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New results boost NuQ for lung and CRC
VolitionRx recently released data for NuQ in colorectal and lung cancer, which both exceeded results from previous trials. In colorectal cancer (CRC), the test when adjusted for age detected 91% of tumors with 90% specificity in its first completed prospective study, unlike previous retrospective studies. The company also released encouraging interim lung cancer data detecting 93% of tumors with 91% specificity using the NuQ test in combination with smoking history, which positions the test a